Preclinical Imaging Market to Grow with a CAGR of 5.94% through 2030

Increase in the drug development is expected to drive the Global Preclinical Imaging Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Preclinical Imaging Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the Global Preclinical Imaging Market stood at USD 5.13 billion in 2024 and is anticipated to grow with a CAGR of 5.94% in the forecast period, 2026-2030. The awareness among individuals regarding Preclinical Imaging has led to favorable market conditions for the global Preclinical Imaging market. Several factors contribute to the growth of various Preclinical Imaging products.

The pharmaceutical and biotechnology sectors are among the most significant consumers of preclinical imaging technologies. These industries rely on preclinical imaging to expedite drug development processes. By assessing drug efficacy and safety in preclinical stages, companies can make informed decisions about candidate compounds, ultimately reducing the time and cost of bringing new therapies to market. The growing trend toward personalized medicine is another key driver. Preclinical imaging plays a pivotal role in tailoring treatments to individual patients based on their unique molecular profiles.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Preclinical Imaging Market”

Preclinical imaging bridges the gap between laboratory discoveries and clinical applications, facilitating translational research. It allows scientists to validate hypotheses, study the feasibility of new treatments, and assess safety and efficacy before advancing to human trials. This reduces the risk associated with clinical trials and expedites the delivery of therapies to patients. The world faces ever-evolving health challenges, from emerging infectious diseases to the rising burden of chronic conditions. Preclinical imaging equips researchers with the tools to explore new avenues of diagnosis and treatment, offering hope in the face of these global health crises, which will further fuel market growth.

In July 2023, GE Healthcare launched a new PET/CT system called Discovery IQ. This system is designed for high-throughput imaging of small animals, and it can be used to image a wide range of diseases, including cancer and neurodegenerative diseases.

Technological advancements have also led to the integration of multiple imaging modalities into a single platform. This approach, known as multi-modal imaging, combines the strengths of different techniques to provide a more comprehensive view of biological processes. Researchers can simultaneously capture anatomical, functional, and molecular information, enhancing the quality and depth of their research, and growing awareness of the importance of Preclinical Imaging are expected to positively impact the global Preclinical Imaging market.

In today's fast-paced world, Imaging helps determine whether a drug candidate is effective in animal models, allowing for swift decision-making on whether to proceed to clinical trials.

preclinical imaging tracks the effects of drugs over time, ensuring their safety and efficacy in a time-efficient manner. Early identification of potential issues through imaging reduces the likelihood of costly late-stage drug failures. The world of healthcare is shifting towards personalized medicine, where treatments are tailored to individual patients. Preclinical imaging contributes by:

Imaging enables the creation of animal models that replicate an individual patient's disease and response to treatment, guiding the development of personalized therapies. By studying disease models and potential treatment outcomes in advance, preclinical imaging aids in optimizing treatment plans, reducing trial and error in patient care.

Global health challenges, such as pandemics and emerging infectious diseases, demand swift responses. Real-time monitoring of pathogens in animal models through imaging helps researchers understand disease progression and develop interventions more rapidly. Imaging plays a key role in assessing the effectiveness of vaccines and treatments against infectious diseases, expediting the development of vital interventions.

The growth of academic and research institutions dedicated to life sciences is driving the demand for preclinical imaging systems and expertise. As more institutions invest in cutting-edge imaging facilities, it creates a ripple effect, propelling the entire industry forward.

In recent years, preclinical imaging has become an indispensable tool in the fields of biomedical research, drug development, and personalized medicine. Its non-invasive and high-resolution imaging capabilities have revolutionized the way scientists study and understand biological processes, diseases, and the effects of potential treatments. Consequently, Preclinical imaging plays a pivotal role in cancer research by allowing scientists to detect, monitor, and characterize tumors in animal models. Imaging techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable insights into tumor size, location, metabolism, and response to treatments. However, the Cost of Technology and Infrastructure may hinder market growth. Moreover, challenges related to regulatory and ethical considerations may pose obstacles to the vitamins market in the near future.

The Global Preclinical Imaging Market is segmented into modality, application, end user and company.

Based on application, the Drug Discovery segment emerged as the fastest growing segment in the global market for Preclinical Imaging in 2024. At the core of this momentum is the surge in R&D investments by pharmaceutical and biotechnology companies aiming to accelerate the development of novel therapeutics. According to recent industry data, over 60% of pharma companies increased their preclinical R&D budgets in 2024, with a significant portion allocated to imaging technologies for compound screening, efficacy analysis, and safety assessment.

Preclinical imaging technologies such as PET, MRI, and bioluminescence imaging offer non-invasive, real-time visualization of drug behavior in living animal models. This significantly improves the ability to assess target engagement, biodistribution, and therapeutic efficacy—key metrics in early-stage drug development. As the drug pipeline becomes more complex, especially in areas like oncology, neurology, and immunotherapy, demand for precise imaging tools has sharply increased.

Additionally, the growing emphasis on personalized medicine and biologics has fueled the need for advanced imaging to study mechanism-specific effects and biomarkers in vivo. This tailored approach relies heavily on preclinical imaging to bridge the translational gap between lab research and clinical trials.

Furthermore, regulatory agencies, such as the U.S. FDA and EMA, continue to encourage early toxicity and pharmacokinetics profiling, a role where imaging plays a vital part. This regulatory push has incentivized pharma companies to adopt imaging early in the drug discovery process to de-risk development pathways. Together, these trends have propelled the Drug Discovery segment to the forefront of growth in the preclinical imaging space, making it a pivotal driver of market expansion in 2024.

The Asia-Pacific region, is the fastest growing region led by countries like China, Japan, and India, is witnessing a surge in investment in research and development (R&D). Governments and private sectors are allocating resources to advance biomedical research, creating opportunities for preclinical imaging. The pharmaceutical market in Asia-Pacific is expanding rapidly. With a growing population and rising healthcare needs, there is a substantial demand for preclinical imaging to support drug discovery and development. Many global pharmaceutical companies are establishing collaborations and partnerships with research institutions and contract research organizations (CROs) in Asia-Pacific. These collaborations drive the adoption of preclinical imaging technologies in the region. Countries like China are investing heavily in healthcare infrastructure, including state-of-the-art research facilities and hospitals. This investment includes the acquisition of advanced imaging equipment. Regulatory bodies in Asia-Pacific countries are making efforts to streamline regulations related to preclinical imaging.

Major companies operating in Global Preclinical Imaging Market are:

• Aspect Imaging Ltd
• Bruker Corporation
• Fujifilm Holdings Corporation
• Mediso Ltd
• MR Solutions Ltd
• PerkinElmer Inc.
• United Imaging Healthcare Co. Ltd
• AXT PTY LTD
• Advanced Molecular Vision, Inc.
• IVIM Technology Corp

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The advancement in the technology and increasing Pharmaceutical and Biotechnology Sectors are key drivers of the preclinical imaging market. In recent years, Traditional techniques have been refined, and new, groundbreaking methods have emerged. For instance, high-resolution micro-computed tomography (micro-CT) has enabled researchers to explore the finest details of anatomical structures in small animals. Moreover, the growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the vitamins and supplements market in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Preclinical Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality (Optical Imaging Systems, Nuclear Imaging Systems, Micro-MRI, Micro-ultrasound, Micro-CT, Photoacoustic Imaging Systems, Other), By Application (Research and Development, Drug Discovery), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Preclinical Imaging Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Preclinical Imaging Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Web:  https://www.techsciresearch.com